Table 1.
List of Primary Breast Samples and Summary of Findings
| Case
|
FGFR2
|
MAGEA
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Focius | Diagnosis | ER | Expression | Methylation | LOH | MSI | Isoform | SNP 676 (C) | SNP 578 (C) | SNP 582 (A) | Expression | Methylation |
| 1 | N | +++ | − | T | T | G | − | +++ | |||||
| T | Invasive duct | + | ++ | ++ | − | + | ++ | ++ | |||||
| 2 | N | + | − | C | C | A | − | − | |||||
| T | Invasive duct | + | + | − | − | − | b | − | − | ||||
| 3 | N | ++ | − | C/T | T | A/G | − | ++ | |||||
| T | Invasive duct | + | − | +++ | + | − | − | ++ | |||||
| 4 | N | + | − | C | C | A/G | − | ++ | |||||
| T | Invasive duct | + | + | − | − | − | + | − | |||||
| 5 | N | ++ | − | T | T | A/G | − | ++ | |||||
| T | Invasive duct | + | − | ++ | − | − | − | ++ | |||||
| 6 | N | ++ | − | b | C | C | A/G | − | ++ | ||||
| T | Invasive duct | + | + | − | + | + | b | − | − | ||||
| 7 | N | + | − | b | C/T | C/T | A/G | − | ++ | ||||
| T | Invasive duct | + | + | − | + | − | b | − | − | ||||
| 8 | N | ++ | − | b | C/T | C/T | A | − | ++ | ||||
| T | Invasive duct | + | + | − | − | − | b | ++ | − | ||||
| 9 | N | ++ | − | b/c | C/T | C/T | A/G | − | + | ||||
| T | Invasive duct | + | − | − | − | + | b | + | + | ||||
| 10 | N | + | − | b/c | T | T | G | + | + | ||||
| T | Invasive duct | + | + | − | − | − | b | − | + | ||||
| 11 | N | +++ | − | C/T | C/T | A/G | − | +++ | |||||
| T | Invasive duct | + | − | +++ | − | − | +++ | − | |||||
| 12 | N | + | − | T | C/T | A | − | − | |||||
| T | Invasive duct | + | + | − | + | + | b/c | − | − | ||||
| 13 | N | ++ | − | C/T | C | G | − | ++ | |||||
| T | In situ duct | + | ++ | − | − | − | − | ++ | |||||
| 14 | T | Invasive duct | + | + | − | C/T | C/T | A/G | − | − | |||
| 15 | T | Invasive duct | + | − | − | C | C/T | A/G | − | ++ | |||
| 16 | T | Invasive duct | + | − | + | C/T | C/T | A/G | − | − | |||
| 17 | T | Invasive duct | + | − | − | C/T | C/T | A/G | +++ | − | |||
| 18 | T | Invasive duct | + | − | − | C | C/T | G | + | − | |||
| 19 | T | Invasive duct | + | − | − | T | T | A/G | − | − | |||
| 20 | N | ++ | − | C | C | A | − | +++ | |||||
| T | Invasive duct | − | + | ++ | − | − | b | ++ | ++ | ||||
| 21 | N | +++ | − | T | T | G | − | ++ | |||||
| T | Invasive duct | − | + | ++ | + | − | b/c | − | ++ | ||||
| 22 | N | + | − | C | C | A | − | − | |||||
| T | Invasive duct | − | − | − | − | + | − | − | |||||
| 23 | N | − | + | − | C/T | C/T | A/G | − | + | ||||
| T | Invasive duct | − | + | − | + | − | − | + | |||||
| 24 | T | Invasive duct | − | − | − | C | C | A | ++ | − | |||
| 25 | T | Invasive duct | − | − | − | C/T | C/T | G | − | ++ | |||
| 26 | N | ++ | − | C/T | C/T | G | − | + | |||||
| T | Invasive duct | − | − | − | − | − | b | − | + | ||||
| 27 | N | +++ | − | C/T | C/T | G | − | +++ | |||||
| T | Invasive duct | − | + | +++ | + | − | +++ | + | |||||
| 28 | N | + | − | C/T | C/T | A/G | − | ++ | |||||
| T | Invasive duct | − | − | − | − | − | −/+ | ++ | |||||
| 29 | T | Invasive duct | − | − | − | C/T | C/T | A/G | − | +++ | |||
| 30 | N | ++ | − | T | T | G | − | +++ | |||||
| T | Invasive duct | − | − | ++ | − | + | b/c | ++ | − | ||||
| 31 | T | Invasive duct | − | − | − | C/T | C/T | G | − | − | |||
N = normal; T = tumor; ER = estrogen receptor; MSI = micro satellite instability; SNP = single nucleotide polymorphism.
“−” indicates negative; “+,” mild positivity; “++,” moderate positivity; “+++,” strong positivity.